A bispecific nanobody to provide full protection against lethal scorpion envenoming

被引:89
作者
Hmila, Issam [1 ]
Saerens, Dirk [3 ,4 ]
Ben Abderrazek, Rahma [1 ]
Vincke, Cecile [3 ,4 ]
Abidi, Naima [1 ]
Benlasfar, Zakaria [2 ]
Govaert, Jochen [3 ,4 ]
El Ayeb, Mohamed [1 ]
Bouhaouala-Zahar, Balkiss [1 ,5 ]
Muyldermans, Serge [3 ,4 ]
机构
[1] Inst Pasteur, Lab Venins & Toxines, Tunis 1002, Tunisia
[2] Inst Pasteur, Serv Unites Anim, Tunis 1002, Tunisia
[3] Vrije Univ Brussel VIB, Cellular & Mol Immunol Lab, B-1050 Brussels, Belgium
[4] Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium
[5] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia
关键词
ANDROCTONUS-AUSTRALIS-HECTOR; HEAVY-CHAIN ANTIBODIES; SINGLE-DOMAIN ANTIBODIES; ANTIVENOM IMMUNOTHERAPY; MONOCLONAL-ANTIBODIES; FUNCTIONAL-EVALUATION; ANTIGEN-BINDING; ALPHA-TOXIN; VENOM; NEUROTOXIN;
D O I
10.1096/fj.09-148213
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Envenoming following scorpion sting is a common emergency in many parts of the world. Our aim was to ameliorate the current 100-kDa horse plasma antivenom serum (PAS)-derived Fab(2)' to more quickly reach the highly diffusible scorpion toxins (7 kDa). We immunized dromedaries with toxins from Androctonus australis hector (Aah) scorpions and cloned the single-domain antibody fragments or nanobodies (15 kDa) from their B cells. Nanobodies against AahI' toxin (with AahII the most toxic compound of the venom) were retrieved from the libraries, and their AahI'-toxin neutralization was monitored in mice. Remarkably, the NbAahI'F12 fully protected mice against 100 LD50 of AahI' administered intracerebroventricularly. Moreover, where PAS failed completely to neutralize 2 LD50 of crude venom injected subcutaneously, the designed bispecific NbF12-10 against AahI'/AahII toxins succeeded in neutralizing 5 LD50. Finally, in a challenge assay in which mice were subcutaneously injected with a lethal dose of scorpion venom, the subsequent intravenous injection of 85 mu g of NbF12-10 protected all mice, even if the whole procedure was repeated 3 times. Furthermore, the NbF12-10 remained fully protective when mice with severe signs of envenoming were treated a few minutes before the untreated mice died.-Hmila, I., Saerens, D., Ben Abderrazek, R., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., El Ayeb, M., Bouhaouala-Zahar, B., Muyldermans, S. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 24, 3479-3489 (2010). www.fasebj.org
引用
收藏
页码:3479 / 3489
页数:11
相关论文
共 32 条
[21]   Using a recombinant bispecific antibody to block Na+-channel toxins protects against experimental scorpion envenoming [J].
Juste, M. ;
Martin-Eauclaire, M. F. ;
Devaux, C. ;
Billiald, P. ;
Aubrey, N. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (02) :206-218
[22]   Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy [J].
Krifi, MN ;
Savin, S ;
Debray, M ;
Bon, C ;
El Ayeb, M ;
Choumet, V .
TOXICON, 2005, 45 (02) :187-198
[23]   Effects of antivenom on Buthus occitanus tunetanus (Bot) scorpion venom pharmacokinetics:: towards an optimization of antivenom immunotherapy in a rabbit model [J].
Krifi, MN ;
Miled, K ;
Abderrazek, M ;
El Ayeb, M .
TOXICON, 2001, 39 (09) :1317-1326
[24]   Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins [J].
Meddeb-Mouelhi, F ;
Bouhaouala-Zahar, B ;
Benlasfar, Z ;
Hammadi, M ;
Mejri, T ;
Moslah, M ;
Karoui, H ;
Khorchani, T ;
El Ayeb, M .
TOXICON, 2003, 42 (07) :785-791
[25]  
Miranda F., 1970, EUR J BIOCHEM, V16, P279
[26]   A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector [J].
Mousli, M ;
Devaux, C ;
Rochat, H ;
Goyffon, M ;
Billiald, P .
FEBS LETTERS, 1999, 442 (2-3) :183-188
[27]   Camel heavy-chain antibodies:: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire [J].
Nguyen, VK ;
Hamers, R ;
Wyns, L ;
Muyldermans, S .
EMBO JOURNAL, 2000, 19 (05) :921-930
[28]  
PACE CM, 1997, PROTEIN STRUCTURE PR, P297
[29]   Engineering of therapeutic antibodies to minimize immunogenicity and optimize function [J].
Presta, Leonard G. .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) :640-656
[30]   Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen [J].
Saerens, D ;
Kinne, J ;
Bosmans, E ;
Wernery, U ;
Muyldermans, S ;
Conrath, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) :51965-51972